Vdex has already denied any connection with Google, but some here just won't let it go...
So, that was your angle in the original post. You want to say that Cs-131 makes chemo unnecessary. How about Iodine and Palladium? Do they make chemo unnecessary? The absence of data on using chemo as an adjuvant in LUNG brachytherapy most likely indicates a lack of interest. You're one of those people who connects dots that don't exist. GL
All cancer is not categorized as high risk. Saying that it is, is your way of promoting this stock, and it's also one of many reasons why you don't understand this investment. It's also why you don't ask the right questions. I don't see any data on using chemo as an adjuvant in LUNG brachytherapy. There's your answer, thourough. Do what you want with it.
Well you didn't ask the question properly! In the case of lung cancer, brachytherapy is an adjuvant to SURGERY, but it hasn't been shown to provide a significant advantage in cancer control over surgery alone.
The combination of brachytherapy with adjuvant chemo HAS been used for breast cancer, but it was with HDR brachytherapy.
Google: Neoadjuvant Interstitial High-Dose-Rate (HDR) Brachytherapy Combined with Systemic Chemotherapy in Patients with Breast Cancer.
Conclusion of that study:
The combination of interstitial HDR brachytherapy and chemotherapy is a well-tolerated and effective neoadjuvant treatment in patients with breast cancer. Compared to EBRT, treatment time is short. Postoperative EBRT of the whole breast—if necessary—is still possible after neoadjuvant brachytherapy. Even though the number of patients does not permit definite conclusions, the results are promising regarding survival and the very low rate of local recurrences.
The answer to your question is, yes.
The primary curative treatment of lung cancer patients is surgery, chemotherapy and/or radiation therapy (either or all depending on the extent of disease).
The treatment of cancer is not as simple as you seem to believe, and brachytherapy is only one of many possible approaches. The specific course of treatment is based on the type and stage of tumor, disease extent and prognosis, and acceptance of risks and benefits.
You don’t receive a diagnosis of cancer and then look at your doc and say “I’ll take the Cesium.” In spite of what you want to believe, it doesn't work that way...
The purpose of the study was to evaluate the outcomes for wedge resection (WR), WR plus brachytherapy (WRB), or stereotactic body radiation therapy (SBRT) for early stage non-small lung cancer.
He doesn't own 3 million shares, nor is anything he says rooted in reality. He's actually been buying all the way down since the high $2s and says he knows when to buy because it feels right? In the past 4 years NOTHING he's predicted has happened. Zip. And he pronounces himself the KING if IsoRay. It's like a bad Hollywood movie script...
I don't think the description of "startup" can be applied any longer, but the company is still run that way. Al was right in his clinical assessment of TS insulin but he was wrong in his assessment of the pharma industry. At this point, AF's recent blog is simply more right than wrong. Afrezza is certainly not an inferior insulin. That's a foul. But the financial issues are accurate enough and the insiders are raping the stock when they should be acting with frugality. Same old story.
The isotopes are NOT one size fits all which is an issue the pumpers here don't want to hear. Brachytherapy is a niche market, and Cesium is a niche within that therapy according to risk category (probably intermediate). Even that is an oversimplification of whether or not it's indicated according to clinical treatment guidelines.
It's all about cancer control. I've been saying that forever, and Cesium is ON PAR with the other isotopes. The verdict whether or not it's really better still has another 10 years of follow up.
Here is the actual conclusion of that study.
Given the general slow growth of prostate cancer and its usual chronic nature, long-term follow-up in the range of 15 years is thought necessary to definitively determine the oncological success of any treatment for clinically localised
prostate cancer. However, until any modality has this length of follow-up, short-term and intermediate-term results should be reported to ensure that newer interventions are on course to provide similar or perhaps improved cancer
control when compared with existing treatment outcomes. If any new modality for the treatment of clinically localised prostate cancer cannot be utilised until 15 years of followup is obtained, very little progress will be made in improving the treatment of this disease. Although 131Cs is the newest isotope being utilised for prostate brachytherapy, this isotope has now been in use since 2004 and it is
important to know whether with at least intermediate term follow-up 131Cs is on course to provide cancer control on par with prostate brachytherapy using the established isotopes 125I or palladium 103 (103Pd).
Patients undergoing prostate brachytherapy with 131Cs have excellent oncological outcomes at 5 years. Although more years of follow-up are required to assess the true cancer control ability of prostate brachytherapy with 131Cs,
these intermediate-term outcomes show that there is no reason at this time to suspect that 131Cs will not provide oncological outcomes AT LEAST ON PAR with those of 125I and103Pd. As follow-up of this patient cohort matures, we will
continue to publish our results to show the long-term oncological outcome of 131Cs prostate brachytherapy.
Live and learn, Amacall. I don't know everything. I did the homework and learned a lot along the way that eventually changed my sentiment. Education is a wonderful thing.
That decision is not in the hands of the patient and the best treatment may be another treatment entirely. The assumptions you make about all of this are not educated assumptions.
US market less than $100M with Europe basically zilch, and the company just bagged GliaSite. But the pumpers are screaming about a $400M market cap and a $12 PPS in the immediate future. Super Mafia is right.
Maybe you've heard or read about the global economy being under pressure, or that the brachytherapy market had a pullback? ISR is financially stable. Krachon wouldn't have accepted a job if it wasn't, but that stability is not from revenues. He'll be busy.
The lack of sales in Europe is due to Cesium being more expensive. Their health system makes them even more price sensitive than the US and his Rolodex won't help that situation much. Europe is perfectly happy with I-125. The rest of your catalysts are all speculative. Babcock was a controlling idiot. LaVoy at least has the sense to delegate.
Frothing at the mouth was my comment about the pumpers and your deleted rumor. Yeah, I know. What rumor? You evidently liked the comment enough to use as your own. I'm flattered.
For the last time, when I was a shareholder of this stock, and when Babcock was playing IR guy, I sent him a brief email on the subject you've mentioned in the interest of perhaps helping the company to expand in South America after the PR about the child in Peru. The motivation was only indirect for me as a shareholder wanting to help the company grow.
Although Dwight had responded to my few emails on other subjects, there was no response to that email and nothing more transpired. The spin that you, or someone else, started about me applying for a job had no basis in fact. No application, no rejection, no nothing. Feel free to perpetuate the spin.
We know now that Babcock had no intention of expansion, and the "feel good" Peru PR has disappeared into history with no follow up or response from the medical community. No one knows if the child survived.
Since then, the company has really done nothing, until recently, with the canning of Babcock and the hiring of some people who actually know the industry. Babcock would never had done that, ever. He wanted it all for himself, and ISR gave in to him for almost a decade. Huge mistake.
So, you and Jimmy and thourough can go on being children here and manipulate the board with silly comments and rumors. I have no financial interest. If Jimmy makes a million dollars and thourough makes a billion, they'll still be idiots. The world is full of them. GL